| name | Teriparatide |
| classification | Parathyroid hormone analog, used for osteoporosis treatment. |
| pharmacokinetics | Teriparatide is administered subcutaneously. It has a relatively short half-life, meaning it's quickly metabolized. Absorption is not fully understood but it likely enters the bloodstream and binds to receptors in bone tissue. Excretion primarily occurs through the kidneys, making dosage adjustments important for patients with kidney issues. |
| suggested dosage | | male patient 25 70kg | 20 mcg/day subcutaneous injection. This dosage is based on available clinical data and guidelines. The dosage should be determined by a healthcare professional in the context of a patient's specific clinical needs. |
|
| indications | | 1 | Treatment of osteoporosis in postmenopausal women with a high risk of fracture. | | 2 | Treatment of osteoporosis in men with a high risk of fracture. | | 3 | Treatment of osteoporosis in those with glucocorticoid-induced osteoporosis. | | 4 | Not usually indicated for general bone health. |
|
| safety in pregnancy | Teriparatide is **contraindicated** in pregnancy. It should not be used during pregnancy. There are insufficient data to determine safety, and theoretical risks to the developing fetus exist. |
| safety in breastfeeding | Teriparatide is **not recommended** during breastfeeding. There is concern over potential transfer into breast milk, and the long-term effects on the infant are unknown. |
| side effects | | 1 | Nausea | | 2 | Headache | | 3 | Dizziness | | 4 | Leg cramps | | 5 | Transient hypercalcemia | | 6 | Increased risk of bone pain | | 7 | Possible increase in the risk of osteosarcoma (very rare) | | 8 | Injection site reactions (pain, redness, swelling) | | 9 | Lightheadedness |
|
| alternatives | | 1 | | | 2 | | drug | Alendronate | | class | Bisphosphonate | | notes | Commonly used in osteoporosis treatment. |
| | 3 | | drug | Risedronate | | class | Bisphosphonate | | notes | Another bisphosphonate with similar mechanism of action. |
|
|
| contraindications | | 1 | Hypersensitivity to teriparatide or any of its components | | 2 | History of hypercalcemia | | 3 | Significant bone abnormalities that may increase risk of fracture or bone pain. | | 4 | Severe kidney impairment |
|
| interactions | | 1 | Concurrent use with other medications affecting calcium metabolism can potentially lead to increased or decreased serum calcium levels, necessitating close monitoring. | | 2 | Inform your healthcare provider about all other medications you are taking. |
|
| warnings and precautions | | 1 | Teriparatide should be administered under strict medical supervision due to the possibility of side effects. Close monitoring of calcium and phosphate levels in the blood is essential. | | 2 | Patients with pre-existing kidney disease require careful dose adjustments and monitoring. | | 3 | Caution is required in patients with a history of bone cancer. | | 4 | Should not be used as long-term treatment. Patients need a transition to other osteoporosis treatments after a defined treatment duration. |
|
| additional informations | | 1 | Teriparatide is a relatively expensive medication. | | 2 | This information is for educational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this site. |
|
| patient details | |
